FMO5 and myelodysplastic syndrome: Peroxiredoxin-2 (PRDX2), a member of the peroxiredoxin family that regulates ROS, was found increased in granulocytes of low risk MDS patients [14]; ROS sources, such as NAD(P)H oxidase (Nox) complexes, regulate gene expression and splicing factors activity in MDS bone marrow [15].